trial

Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination

NCTId NCT02426983
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 12 (estimated)
Sponsored by University of Ottawa
Primary completion 2015-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
12 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2015-04
Primary completion
2015-09
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Direct Current StimulationDextromethorphan

Sponsors

University of OttawaLead Sponsor

Investigators

1
Danielle Impey, Ph.D. (cand.)Principal Investigator

Sites

1 total
Ottawa, Canada

Linked catalysts

1
Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Sti — primary completion2015-09

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1,PHASE2
Primary Completion Date
2015-09
Status
UNKNOWN
relationships
The graph out of here
drug
Direct Current Stimulation
drug
Dextromethorphan
drug
lead_sponsor
University of Ottawa
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Danielle Impey, Ph.D. (cand.)
person